Clinical trials: Biliary Cancers
Biliary Tract Cancer
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.
- Trial name
- TOURMALINE (NCT05771480)
- Testing
- Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin
- Where
- 34 sites in United States, France and 6 more
- Volunteers
- 142 people
- Sponsor
- AstraZeneca
Testicular Germ Cell Cancer
Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity
This is a study exploring measurable markers in the blood of patients with testicular tumors. The investigators will focus on the importance of measuring and analyzing these markers for their prognostic value and predictive…
- Trial name
- TG-BIL (NCT07463508)
- Testing
- blood sampling, Tissue sampling
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Clermont-Ferrand
Gastric Cancer in Situ, Pancreatic Cancers
Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers
The primary purpose of the study is to determine the maximal tolerated dose (MTD) of Oxaliplatin in this phase I study. The secondary objectives are to determine the response rate, progression free survival, overall survival, and…
- Conditions
- Gastric Cancer in Situ, Pancreatic Cancers, Biliary Cancers
- Trial name
- SOLAR (NCT03162510)
- Testing
- Oxaliplatin, Albumin-Bound Paclitaxel /nab-Paclitaxel, S-1
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- National Health Research Institutes, Taiwan
Primary Sclerosing Cholangitis, Cholangiocarcinoma
Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
This observational study of a national cohort of 600 Swedish PSC patients include yearly MR/MRCP, biobanking of serum, plasma and blood, followup clinical data (interventions, symptoms, labs, colonoscopy).
- Trial name
- PSC (NCT03041662)
- Testing
- MR/MRCP
- Where
- Sweden
- Volunteers
- 620 people
- Sponsor
- Karolinska University Hospital
Advanced Solid Tumors, Ewing Sarcoma
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
- Conditions
- Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07197554
- Testing
- ST-01156
- Where
- 6 sites in United States
- Volunteers
- 171 people
- Sponsor
- SEED Therapeutics, Inc.
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic…
- Trial name
- MTAPESTRY 103 (NCT06360354)
- Testing
- Anvumetostat, Gemcitabine, Nab-paclitaxel
- Where
- 77 sites in United States, Australia and 14 more
- Volunteers
- 120 people
- Sponsor
- Amgen
Biliary Tract Cancer, Cholangiocarcinoma
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
This study is being done to see if the investigators can improve the outcome of patients with biliary tract cancer that do not qualify for surgery.
- Trial name
- NCT06546969
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Maryland, Baltimore
Cholangiocarcinoma, Malignant Digestive System Neoplasm
Molecular Epidemiology of Biliary Tree Cancers
This study is to learn if certain risk factors (environmental, viral, behavioral, medical, and dietary), tumor markers, and genetic changes can predict the development and outcome of biliary tree cancers.
- Trial name
- NCT05179486
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- M.D. Anderson Cancer Center
Cholangiocarcinoma, Bile Duct Carcinoma
Clinico-demographic Profile of the Patient With Pancreaticobiliary Malignancy Undergoing ERCP in a Tertiary Care Center of Nepal
Background Pancreaticobiliary malignancy (PBM) is a group of cancers affecting pancreas and bile duct. The diagnosis is often late and with fatal outcomes.
- Conditions
- Cholangiocarcinoma, Bile Duct Carcinoma, Endoscopic Retrograde Cholangio-Pancreatography, Pancreatic Neoplasms
- Trial name
- NCT06888401
- Testing
- ERCP
- Where
- Nepal
- Volunteers
- 597 people
- Sponsor
- Kathmandu University School of Medical Sciences
Hepatocellular Carcinoma, Biliary Tract Cancer
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
This research study is studying a combination of drugs as a possible treatment for Hepatocellular Carcinoma or Biliary Tract Cancer. The interventions involved in this study are: Durvalumab Tremelimumab Radiation Therapy
- Trial name
- NCT03482102
- Testing
- Tremelimumab, Durvalumab, Radiation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Cholangioadenoma
RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor
The purpose of this study was to explore the safety and efficacy of raltitrexed combined with oxaplatin as second line treatment for advanced malignant biliary system tumor.
- Trial name
- RALOXBTC (NCT05148143)
- Testing
- Raltitrexed combined with oxaplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cholangiocarcinoma, Biliary Cancer
Neoadjuvant Therapy in Biliary Adenocarcinoma
Feasibility of neoadjuvant therapy in resectable biliary adenocarcinoma.
- Trial name
- NCT04480190
- Testing
- Gemcitabine, Cisplatin, Fluorouracil
- Where
- United States
- Sponsor
- Jordan Kharofa
Biliary Tract Neoplasm, Cholangiocarcinoma
MRCP Diagnoses EHCC Better When Combined DWI
Researching the diagnostic significance of Biliary Tract Neoplasm under combining DWI sequence with MRCP versus MRCP only separately.
- Trial name
- NCT01595217
- Testing
- 3T MRI
- Where
- China
- Volunteers
- 99 people
- Sponsor
- China Medical University, China
Biliary Tract Neoplasms, Pancreatic Neoplasms
RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction
Less than 20% of patients with malignant distal bile duct (BD) obstruction (often pancreatic cancer) are suitable for resection surgery.In the rest,palliation treatment comes into focus.
- Conditions
- Biliary Tract Neoplasms, Pancreatic Neoplasms, Stent Occlusion
- Trial name
- NCT00980889
- Testing
- Steel, Nitinol
- Where
- 11 sites in Sweden
- Volunteers
- 400 people
- Sponsor
- Stockholm South General Hospital
Gallbladder Cancer, Biliary Tract Cancer
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
In the United States, the incidence of biliary tract cancer and gallbladder cancer has been estimated to be 6,000-8,000 patients per year.
- Trial name
- NCT00123825
- Testing
- Gemcitabine, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Biliary Tract Cancers
A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
This is a prospective, single-arm, Phase II study evaluating sacituzumab tirumotecan combined with envafolimab in patients with TROP2-positive advanced biliary tract cancers who have progressed on first-line immunochemotherapy.
- Trial name
- NCT07729033
- Testing
- Sacituzumab tirumotecan combined with envafolimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Malignant Ascites
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
This projectis aim to evaluate the efficacy of immune checkpoint inhibitor (pembrolizumab or nivolumab) on the malignant ascites of patients with advanced gastric, pancreatic and biliary tract cancers.
- Trial name
- NCT05745233
- Testing
- Nivolumab, Pembrolizumab
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Pancreatic Cancer, Bile Duct Cancer
Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy
This study aims to evaluate whether the incidence of delayed gastric emptying (DGE) can be reduced by proximal Roux-en-y gastrojejunal anastomosis in comparison with the standard gastrojejunal anastomosis in pylorus-resecting…
- Conditions
- Pancreatic Cancer, Bile Duct Cancer, Duodenal Cancer
- Trial name
- NCT02954302
- Testing
- PrPD with proximal Roux-en-y gastrojejunal anastomosis, conventional PrPD
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Gallbladder Diseases, Healthy
Multicenter Prospective Cohort Study of Risk Factors for Gallbladder Cancer
This trial is a prospective study, the main purpose of the study is to investigate the association between benign gallbladder disease and gallbladder carcinoma; to explain the timing of intervention, intervention and early…
- Trial name
- NCT03762837
- Testing
- Benigh gallbladder diseases
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Colorectal Cancer, Gastro Esophageal Junctional Cancer
IKS04 Regimen in Advanced Solid Tumors That Express CA242
This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further…
- Conditions
- Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
- Trial name
- NCT07738939
- Testing
- IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Iksuda Therapeutics Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.